Stockreport

BeyondSpring’s Lead Asset, Plinabulin, Continues to Demonstrate Clinical Superiority Versus Standard of Care for Neutropenia

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF Phase 2 Data Show Plinabulin Significantly Reduces Thrombocytopenia in Docetaxel-Treated Patients Compared to Standard of Care Data Presented at 2018 IASLC World Confer [Read more]